ABSTRACT
La disfunción eréctil es la incapacidad persistente o recurrente para conseguir y/o mantener una erección suficiente como para conseguir una relación sexual satisfactoria. Se trata de un problema de circulación sanguínea. Los inhibidores de la fosfodiesterasa 5 (IPD5), sildenafilo, tadalafilo, vardenafilo, avanafilo, son fármacos de efectividad muy alta; al 70% de los pacientes les funciona. Son, asimismo, fármacos seguros, tan solo contraindicados en los pacientes que tienen prohibido el ejercicio físico (tras alguna cirugía) o que reciben medicamentos liberadores de nitratos, como nitroglicerina (en parches o comprimidos) o mononitrato y dinitrato de isosorbida. En el presente trabajo se plantean diferentes situaciones de uso de estos medicamentos y cómo actuar ante la demanda de estos fármacos por el paciente realizando una correcta evaluación de sus circunstancias y explicándole de manera adecuada la importancia de una evaluación previa a su prescripción por el médico (AU)
Erectile dysfunction is the persistent or recurring inability to achieve and/or maintain enough of an erection to be able to engage in satisfactory sexual intercourse. This is an issue linked to blood circulation. Phosphodiesterase-5 inhibitors (PDE5) - sildenafil, tadalafil, vardenafil and avanafil - are highly effective drugs. They work with 70% of patients. Additionally, they are safe drugs that are only contraindicated for patients that must not engage in physical exercise (after a surgery) or that have been prescribed nitrate-releasing drugs such as nitro-glycerine (in patches or pills) or mononitrate and isosorbide dinitrate. This paper describes various scenarios where these drugs are used and how to act when the patient asks for these drugs, by correctly assessing their circumstances and appropriately explaining the importance of having a check done before the drugs are prescribed by the doctor (AU)
Subject(s)
Humans , Male , Erectile Dysfunction/drug therapy , Drug Prescriptions/standards , Pharmacy/methods , Phosphodiesterase 5 Inhibitors/therapeutic use , Community Pharmacy Services/organization & administration , Community Pharmacy Services/standardsSubject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/physiopathology , Hyperglycemia/drug therapy , Hyperglycemia/etiology , Drug Therapy, Combination , Glycated Hemoglobin , Humans , Hyperglycemia/diagnosis , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Metformin/therapeutic useSubject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/physiopathology , Hyperglycemia/drug therapy , Hyperglycemia/etiology , Drug Therapy, Combination , Glycated Hemoglobin/analysis , Humans , Hyperglycemia/diagnosis , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Metformin/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Needs Assessment , Electronic Mail , Internet , Delivery of Health Care/organization & administration , Health Services Accessibility/trends , Electronic Mail/organization & administration , Electronic Mail/standards , Telecommunications/organization & administration , Telecommunications/standardsABSTRACT
La Farmacia Comunitaria es capaz de realizar tareas de farmacovigilancia, y de participar en programas orientados a un fármaco o grupo de fármacos. Objetivo: Iniciar a los farmacéuticos comunitarios en el seguimiento de pacientes y la cumplimentación de encuestas útiles en las campañas de Farmacovigilancia. Métodos: Entre mayo y diciembre de 1998 se realizó una campaña de detección de reacciones adversas de inhibidores de la bomba de protones: omeprazol, pantoprazol y lansoprazol. Se recogieron datos demográficos de los usuarios y se realizaron hasta 3 entrevistas con cada uno de ellos. Resultados: Respondieron 21 farmacias comunitarias que entrevistaron a 287 pacientes. Aparecieron 54 sospechas de reacciones adversas, de las que 10 fueron calificadas como improbables por el Centro de Farmacovigilancia de Aragón, otras 10 se atribuyeron a falta de efectividad del fármaco y las 34 restantes fueron calificadas de posibles o probables: 31 leves y 3 moderadas (AU)
Community pharmacy is capable of carrying out drug surveillance tasks and of participating in programs orientated towards a drug or group of drugs. Objective: To initiate community pharmacies in patient follow-up and the compliance of useful surveys in drug surveillance campaigns. Methods: A campaign was carried out between May and December 1998 to detect adverse drug reaction to the proton pump inhibitors: omeprazole, pantoprazole and lansoprazole. Demographic user data was obtained and up to three interviews were made on each one of them. Results: 21 community pharmacies replied that interviewed 287 patients. 54 suspected adverse drug reactions appeared, of which 10 were qualified as improbable by the Aragon Drug Surveillance Center. Another 10 were attributed a lack of drug effectiveness and the remaining 34 were qualified as possible or probable: 3/ slight and 3 moderate reactions Conclusion: Community pharmacy can collaborate actively with Drug Surveillance Centers in adverse drug reactions detection campaigns (AU)
